Loading
A phase 1/2 trial of TQB2102 in biliary tract cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT06431490 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 102 participants planned, started 2024-07-22 and due to reach its primary completion in 2027-05. Interventions recorded: TQB2102 for injection.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares TQB2102, Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing) and the tag pipeline.